Background: The incidence of testicular germ cell tumors (TGCT) is increasing steadily in the United States, particularly among Latinos. TGCT is thought to be initiated in utero and exposure to endocrine-disrupting chemicals, suspected contributors to TGCT pathogenesis, during this critical developmental period may contribute to the rise.
Objectives: To assess the relationship between fetal exposure to agricultural endocrine-disrupting pesticides (EDPs) and TGCT risk among adolescents in a diverse population in California.
Methods: We conducted a registry-based case-control study of TGCT. Cases, diagnosed between 1997 and 2011, were 15-19 years of age (n = 381). Controls were matched on birth year and race/ethnicity (n = 762). Quantities (kilograms) of 33 pesticides applied within 3 km and 1 km radii of each individual's address before birth were estimated using the Pesticide Use Reporting database. Odds ratios (OR), 95% confidence intervals (CI), and population attributable risk (PAR) were calculated for each EDP (using log-2 transformed values). Risk models considered race/ethnicity, birth year, and neighborhood socioeconomic status.
Results: A doubling of nearby acephate applications (3 km and 1 km radii) and malathion applications (1 km radius) was associated with increased risks of TGCT among Latinos only (OR = 1.09; 95% CI:1.01-1.17; 1.30; 95% CI:1.08-1.57, and 1.19; 95% CI:1.01-1.39, respectively), whereas application of carbaryl within a 3 km radius increased TGCT risk in non-Latinos only (OR = 1.14, 95% CI:1.01-1.28). We estimate that acephate was associated with approximately 10% of the TGCT PAR, malathion with 3% and carbaryl with 1%.
Conclusions: TGCT among adolescents in California was associated with prenatal residential proximity to acephate and malathion among Latinos, and with carbaryl among non-Latinos. These results suggest that the rise in TGCT risk among Latinos may be associated with exposure to these pesticides.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijheh.2021.113881 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Networks of pre-diagnostic circulating RNA in testicular germ cell tumour.
Sci Rep
January 2025
Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
Testicular germ cell tumour (TGCT) is a malignancy with known inherited risk factors, affecting young men. We have previously identified several hundred differentially abundant circulating RNAs in pre-diagnostic serum from TGCT cases compared to healthy controls. In this study, we performed Weighted Gene Co-expression Network Analysis (WGCNA) on mRNA and miRNA data from these samples.
View Article and Find Full Text PDFTreatment of Tenosynovial Giant Cell Tumor of the Cervical Spine with Postoperative Anti-RANKL Antibody (Denosumab) Administration.
Acta Med Okayama
December 2024
Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Tenosynovial giant cell tumor (TGCT) is a fibrous histiocytic tumor originating in the synovial membrane. While cervical TGCT may not be considered a common diagnosis preoperatively because it is relatively rare, it has a high recurrence rate and should be considered. Total resection is preferable, but it can be challenging due to the risk of damaging the vertebral artery.
View Article and Find Full Text PDFExploiting potential molecular compounds for treating testicular seminoma by targeting immune related genes.
Cell Commun Signal
November 2024
Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Article Synopsis
- Advanced seminoma patients face a serious challenge with up to 30% exhibiting resistance to cisplatin, leading to a high mortality risk, and limited treatment options beyond traditional therapies like chemotherapy and radiotherapy.
- A study utilized advanced statistical methods to identify immune-related genes, leading to the development of a prognostic signature that predicts patient survival more accurately than existing risk factors.
- Results indicated that patients identified as high-risk had significantly lower progression-free survival, and certain molecular compounds could effectively target the identified genes, suggesting potential for immunotherapy in these patients.
Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review.
Eur Urol
November 2024
Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Article Synopsis
- - Testicular germ cell tumors (TGCTs) are rare but their incidence is rising globally, with varying rates across different regions and ethnicities. This review examines the changing patterns and identifies risk factors associated with TGCT.
- - The research included a systematic review of 53 reports, revealing that genetic predisposition accounts for about 44% of TGCT heritability, as well as various risk factors like in utero chemical exposure and behavioral issues such as marijuana use.
- - Conclusions suggest that the increase in TGCT cases may be linked to socioeconomic changes and migration, necessitating further research and better screening programs to address the rising incidence.
Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis.
Sci Rep
October 2024
The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, Gansu, China.
Lymphocyte activating gene-3 (LAG3) is a distinctive T cell co-receptor that is expressed on the surface of lymphocytes. It plays a special inhibitory immune checkpoint role due to its unique domain and signaling pattern. Our aim is to explore the correlation between LAG3 in cancers and physiological processes related to a range of cancers, as well as build LAG3-related immunity and prognostic models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!